

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

Fabrication of 3D printed hollow microneedles by Digital Light Processing (DLP) for the buccal delivery of actives

Journal:	<i>ACS Biomaterials Science & Engineering</i>
Manuscript ID	ab-2023-00116h
Manuscript Type:	Article
Date Submitted by the Author:	27-Jan-2023
Complete List of Authors:	Monou, Paraskevi-Kyriaki; Aristotle University of Thessaloniki, Department of Pharmacy Andriotis, Eleftherios; Aristotle University of Thessaloniki Tsongas, Konstantinos ; International Hellenic University Tzimtzimis , Emmanuel ; International Hellenic University Katsamenis, Orestis; University of Southampton Tzetzis, Dimitrios; International Hellenic University School of Science and Technology Anastasiadou, Pinelopi ; Aristotle University of Thessaloniki Vizirianakis, Ioannis; Aristotle University of Thessaloniki, Pharmaceutical Sciences Andreadis, Dimitrios; Aristotle University of Thessaloniki Fatouros, Dimitrios; Aristotle University of Thessaloniki, School of Pharmacy

SCHOLARONE™
Manuscripts

1
2
3
4 1 Fabrication of 3D printed hollow microneedles by
5
6
7
8 2 Digital Light Processing (DLP) for the buccal
9
10
11
12 3 delivery of actives
13
14
15
16

17 4 *Paraskevi Kyriaki Monou^{1,2}, Eleftherios G. Andriotis¹, Konstantinos Tsongas^{3,4}, Emmanouil K.*
18
19
20 5 *Tzimtzimis³ Orestis L. Katsamenis⁵, Dimitrios Tzetzis³, Pinelopi Anastasiadou⁶, Ioannis S.*
21
22
23 6 *Vizirianakis^{2,7,8}, Dimitrios Andreadis⁵, Dimitrios G. Fatouros^{1,2,*}*
24
25
26
27

28 7 ¹Department of Pharmacy Division of Pharmaceutical Technology, Aristotle University of
29
30
31 8 Thessaloniki, Thessaloniki 54124, Greece;
32
33
34

35 9 ²Center for Interdisciplinary Research and Innovation (CIRI-AUTH), 57001 Thessaloniki, Greece
36
37

38 10 ³ Digital Manufacturing and Materials Characterization Laboratory, International Hellenic
39
40
41 11 University, School of Science and Technology, Thessaloniki57001, Greece;
42
43
44

45 12 ⁴Department of Industrial Engineering and Management, International Hellenic University, 57001
46
47
48 13 Thessaloniki, Greece;
49
50

51
52 14 ⁵µ-VIS X-ray Imaging Centre, Faculty of Engineering and Physical Sciences, University of
53
54
55 15 Southampton, Southampton, United Kingdom; SO17 1BJ, UK
56
57
58
59
60

⁶Department of Oral Medicine/Pathology, School of Dentistry, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece;

⁷Department of Pharmacy, Laboratory of Pharmacology, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece;

⁸Department of Life and Health Sciences, University of Nicosia, CY-1700 Nicosia, Cyprus

KEYWORDS

Microneedles, hollow, buccal delivery, 3D printing, macromolecules, Digital Light Processing (DLP), microfocus Computed Tomography (μ CT)

ABSTRACT

In the present study, two different microneedle devices were produced using Digital Light Processing (DLP). Two different shapes of needles namely; hexagonal and syringe-like needles were evaluated regarding their mechanical properties and their ability to penetrate the buccal mucosa to effectively deliver actives with molecular weight between 600 – 4000 Da. Attached reservoirs were designed and printed along with the arrays as a whole device. Light microscopy was used to quality control the printability of the designs, whereas non-destructive volume imaging

1

2

3

432 by means of microfocus Computed Tomography (μ CT) was employed for dimensional- and defect

5

6

733 characterisation of the DLP printed devices. The buccal tissue penetration process was studied

8

9

1034 using penetration test and finite element (FE) analysis, which showed that maximum stress

11

12

1335 experienced by the needles during the insertion process was below their ultimate compressive

14

15

16

1736 strength. Permeation studies showed the increased permeability of two model drugs when

18

19

2037 delivered with the MN devices. The safety of these printed devices for buccal administration was

21

22

23

2438 confirmed by histological evaluation and cell viability studies using TR146 cell line.

25

26

2739

28

29

30

3140

32

33

34

3541

36

37

38

39

4042

41

42

4343 **Introduction**

44

45

46

4744 The buccal mucosa has been widely explored for drug delivery because of its large surface, high

48

49

5045 permeability, and rapid repair ¹. Buccal route of delivery offers many advantages such as avoiding

51

52

53

5446 first-pass effect, avoiding protein destruction by gastric enzymes, and enhanced patient

55

56

57

58

59

60

compliance². Moreover, both local and systemic treatment can be applied with the buccal administration of drugs ³. Many dosage forms have been produced for buccal applications, including films ⁴, tablets ⁵, nanoparticles ⁶, and gels ⁷.

Microneedles (MNs) for buccal applications have been explored for applications like vaccination and the delivery of macromolecules like insulin ^{8,9}. MNs were first introduced for transdermal delivery of active pharmaceutical ingredients (APIs) such as hormones¹⁰, vaccines¹¹, antibiotics¹², and glucocorticoids¹³. Buccal MN arrays are promising for the effective treatment using peptides and proteins. Dosing proteins through the oral route is impossible since they degrade in the gastrointestinal tract and have low membrane permeability. Their administration is limited to the parenteral routes which cause fear and discomfort to patients, mainly in the paediatric and geriatric populations ². Different types of MNs were fabricated for skin delivery including solid, hollow, and coated MNs¹⁴, using techniques like laser cutting, laser ablation, electrodeposition, lithography, etching, and micromolding as manufacturing processes¹⁵. Additive manufacturing (AM), a newly introduced technology, has also been employed for MN fabrication¹⁶.

AM and 3D printing, in particular, allow the layer-by-layer manufacturing of complex 3D structures with high precision¹⁷. Compared to the traditional fabrication processes, 3D printing

63 controls the topological diversity of the MN arrays and it is cost-efficient as a one-step procedure¹⁸.

64 Digital Light Processing (DLP) 3D printing is based on photopolymerization of a liquid resin to

65 create solid objects with high resolution and accuracy, compared to other 3D printing

66 techniques^{19,20}. Thus, it is the most appropriate 3D printing process for the production of MN

67 arrays as DLP provides the opportunity to construct objects with microscopic features such as

68 micron-sized needles (< 1000 μm) and their elaborate shapes (e.g. cone²¹, pyramid²², syringe-

69 like²³). 3D printing of MNs has recently emerged in the field, offering new potential to the

70 transdermal and buccal drug delivery market, based on the unique asset of 3D printing, the easy

71 and fast customization. 3D printing promotes personalized therapy and enables the flexibility to

72 develop on-demand devices, fully adapted to the patient's needs. Moreover, this customization is

73 cost-effective, and fast, allowing multifunctional treatment by combining more than one APIs in a

74 single device¹⁶.

75 Both solid and hollow MNs have been developed using 3D printing technologies. Their production

76 is mostly based on vat photopolymerization, namely Stereolithography (SLA), Digital Light

77 Processing (DLP), Two-Photon Polymerization (2-TPP), Liquid-Crystal Display (LCD) and

78 Digital Light Processing (DLP). Generally, most of the above technologies have been employed

1
2
3
4 79 for transdermal MN patches or devices. SLA has been used for the production of MNs for
5
6
7 80 transdermal delivery of model dyes²⁴ and insulin²⁵. Transdermal delivery of insulin has also been
8
9
10 81 tested using 3D printed hollow MNs using SLA²³ and LCD²⁶. Hollow MNs were also printed with
11
12
13 82 DLP to explore the feasibility of the method and to optimize the critical parameters for the
14
15
16
17 83 successful fabrication of hollow MN arrays²⁷. In addition to these techniques, 2-TPP, the most
18
19
20 84 expensive and accurate 3D printing method ²⁸, has been employed for the production of
21
22
23
24 85 biocompatible MNs for dermal applications²⁹ and also the production of MNs with antimicrobial
25
26
27 86 properties³⁰.
28
29
30 87 MNs for buccal applications are currently being explored for both local and systemic effects. MN
31
32
33
34 88 penetration to the buccal tissue seems to be less painful than the other sites of the oral cavity
35
36
37 89 (tongue, palate, gingiva, and lip)³¹. MN patches with topical anesthetics reduced the pain from
38
39
40 90 dental injections by causing minimum discomfort to the patients³². Coated MNs with anti-cancer
41
42
43
44 91 drugs were evaluated for the treatment of oral carcinomas³³. Moreover, buccal MN patches have
45
46
47 92 been tested for vaccine administration, promoting the immunological response^{8,34}. Finally, MN
48
49
50 93 patches for delivering macromolecules have also been reported, suggesting that these drug delivery
51
52
53
54
55
56
57
58
59
60

1

2

3

494 systems could potentially improve adherence and facilitate drug delivery to the paediatric

5

6

795 population⁹.

8

9

1096 In the present study, two different shapes of MNs were printed using DLP. Attached reservoirs

11

12

13

1497 and luer locks were designed and printed as whole devices to facilitate the infusion through the

15

16

1798 MN channels. These devices hold promise for an array of medicines for special populations like

18

19

2099 paediatric and geriatric patients³⁵. This approach might overcome the pitfalls of the existing

21

22

23

24100 methodologies by enhancing the acceptability of medicines, meet the individual needs of patients,

25

26

27101 mainly children and elders, and hence improve their health. For example, elderly people with

28

29

30102 swallowing difficulties (dysphagia, xerostomia) due to polypharmacy might miss their medication

31

32

33

34103 leading to poor outcomes (worse symptoms) and slow recovery. The current approach can improve

35

36

37104 medication adherence creating at the same personalized medicine for patients.

38

39

40

41105

42

43

44

45106 **Materials and Methods**

46

47

48

49107 **Materials**

50

51

52108 Biocompatible Class I resin (Dental SG) was purchased from Formlabs (Somerville,

53

54

55

56109 Massachusetts, United States). Isopropyl alcohol (99.9%), fluorescein isothiocyanate–dextran

57

58

59

60

(FITC-dextran) (MW 4000%Da), calcein (MW 622.54), and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Ham's F12 (with l-glutamine) was purchased from Lonza (Basel, Switzerland). All other reagents were of analytical grade.

Microneedle design and fabrication

The microneedle (MN) arrays (7 x 7) were originally designed using SolidWorks CAD software (Dassault Systemes, SolidWorks Corporation, Waltham, MA, USA) and STL files were created. The CADs used for the FEA simulations were designed using SolidWorks CAD software (Dassault Systemes, SolidWorks Corporation, Waltham, MA, USA). The MNs were designed with two different shapes namely; hexagonal (array I) and syringe-like (array II) needles. Their height was designed to be 700 μm , the layer height was 50 μm and the whole patch was circular with a 20 mm diameter. Attached reservoirs to both arrays were designed and printed as a whole device. The MN devices were fabricated using a DLP printer (XYZ PartPro100 xP, Taiwan) using Dental SG, a biocompatible resin as the printing material. After printing, the MNs were washed out with

1

2

3

4125Isopropyl Alcohol (15 min) and cured under ultraviolet radiation for 45 min to ensure the full

5

6

7126polymerization of the resin.

8

9

10127

11

12

13

14128**Microscopy**

15

16

17

18129The 3D printed MNs were visualized using a digital light microscope (Dino-Lite AB7013MZE,

19

20

21130AnMo Electronics, Hsinchu, Taiwan) to confirm their shape fidelity and to examine the

22

23

24131morphology of the needles. Their dimensions were measured with aid of the software DinoLite

25

26

27

281322.0. The MNs were inserted in a charge reduction sample holder and visualized with a Desktop

29

30

31133Phenom ProX scanning electron microscope (ThermoFischer, USA)

32

33

34134

35

36

37

38135**Mechanical properties**

39

40

41136Compression tests were performed in both arrays to evaluate the fracture strength of the MNs. A

42

43

44137tensile test machine equipped with a 500 N load cell (M500-50AT Testometric Company,

45

46

47

48138Rochdale, UK) was employed and the arrays were mounted on the metal rod with double adhesive

49

50

51139tape. The metal rod was programmed to descend at a speed of 0.5 min/mm onto a metal plate

52

53

54

55

56

57

58

59

60

ACS Paragon Plus Environment

1
2
3
4 140 causing the compression failure of the MNs. The compression force was over 300 N, a value much
5
6
7 141 higher than the usual forces a MN array experiences during skin or buccal penetration^{24,36}.
8
9

10 142
11
12

13
14 143 **Volumetric Imaging and characterisation by mean of microfocus Computed Tomography (μ CT)**
15

16
17 144 *μ CT imaging:* μ CT imaging was conducted to evaluate the volumetric characteristics of the printed
18
19
20 145 objects, with specific focus on the needles. μ CT imaging was performed using a customised μ CT
21
22
23 146 scanner optimised for 3D X-ray histology (www.xrayhistology.org) based on Nikon's XTH225ST
24
25
26
27 147 system (Nikon Metrology UK Ltd) at the Biomedical Imaging Unit / University Hospital
28
29
30 148 Southampton. Imaging was conducted at 80 kVp / 125 μ A without any beam pre-filtration. A 2850
31
32
33 149 x 2850 dexels detector was used and the source to detector and source to object distances were 938
34
35
36
37 150 mm and 62.5 mm respectively resulting in a voxel size of 15 μ m. Imaging parameters were as
38
39
40 151 follows: 2001 projections were collected over the 360° rotation, with 4 frames per projection being
41
42
43
44 152 averaged for each projection to improve the signal to noise ratio.
45
46

47 153 *Reconstruction of the volume data, image processing and analysis:* Following completion of each
48
49
50 154 acquisition, projection data were automatically reconstructed into 32-bit volumes by means of
51
52
53
54 155 Nikon's own reconstruction engine which uses a filtered-back projection algorithm. Each dataset
55
56
57
58
59
60

1
2
3
4 156 was then resliced (re-oriented in space) and cropped in using Fiji / ImageJ³⁷ and the volumes were
5
6
7 157 saved in 8-bit files. Volumetric analysis and visualisation were conducted in “Dragonfly” (v.
8
9
10 158 2022.1; Object Research Systems (ORS) Inc, Montreal, Canada, 2020; software available at
11
12
13 159 <http://www.theobjects.com/dragonfly>). The needles from each component were segmented using
14
15
16
17 160 thresholding and manual refinement. Analysis was conducted using the connected components
18
19
20 161 tool applied on the segmented needle object.
21
22
23
24
25 162
26
27
28

29 163 **Penetration test using buccal mucosa and Finite Element Analysis (FEA)**

30
31
32 164 Sufficient insertion of the MNs into the buccal tissue is imperative for proper drug delivery.
33
34
35 165 Penetration tests for array 1 and array 2 were conducted using the Testometric tensile machine
36
37
38
39 166 (Rochdale, UK). Buccal tissue from pigs was collected from a local abattoir and was immediately
40
41
42 167 transferred to the lab for preparation. The tissue was mounted onto a cork plate with pins and the
43
44
45 168 arrays were attached to the moving cylindrical probe using double-sided adhesive tape. The MNs
46
47
48
49 169 were inserted into the buccal mucosa at a speed of 0.5 mm/min. The experiment was stopped when
50
51
52 170 the load was exerted from the MNs to the buccal tissue. After insertion, the MNs were inspected
53
54
55
56 171 with a digital microscope to further examine their deformation and their geometric alteration. An
57
58
59
60

1
2
3
4 172 explicit dynamics Finite element analysis (FEA) based on the ANSYS code was performed to
5
6
7 173 simulate the behaviour of the microneedles and the buccal tissue during the insertion process. This
8
9
10 174 model will provide an estimation of the stress behaviour of the microneedles under the insertion
11
12
13
14 175 process, along with the safety factor of the structure.
15
16
17

18 176

19
20
21
22 177 **Permeation studies**
23
24

25 178 Permeation studies were conducted in vertical Franz cells using aqueous solutions of FITC-dextran
26
27
28 179 (1 mg/mL) and calcein (1mg/mL) as model APIs. Porcine buccal mucosa was mounted between
29
30
31
32 180 the donor and the acceptor. The acceptor was filled with PBS (pH 7.4, 37 °C) and the MN devices
33
34
35 181 were placed onto the buccal tissue for 30 and 60 sec at different flow rates using a syringe pump
36
37
38 182 (NE-100, New Era Pump Systems Inc., New York, USA). High flow rates (0.5 - 0.2 mL/min)
39
40
41
42 183 resulted in the leaking of the solution, thus a flow rate of 0.05 mL/min was selected for the study.
43
44
45 184 The permeation profile was monitored for 4h. The two dyes were quantified by fluorescence
46
47
48
49 185 spectroscopy (RF-5301-PC Fluorescence Spectrophotometer, Shimadzu, Kyoto, Japan): excitation
50
51
52 186 490 nm and emission 520 nm.
53
54

55 187
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Histological evaluation

To ensure the safety of the printed MNs and to study the effect of the MN array on the tissue microanatomy, a histological evaluation was performed. Porcine mucosa samples were pierced with array 1 and array 2 for 30 and 60 sec. The samples were fixed in formaldehyde solution and subsequently embedded in paraffin oil. 4 μm thickness sections were taken using a cryostat, stained with hematoxylin eosin dye solutions, and visualized with an optical microscope (Olympus CX31, Olympus, Tokyo, Japan).

Cell viability-MTT assay

Cell viability studies were carried out to investigate the cytotoxic effect of the resin used to produce the MNs. Three printed cubes (1 cm^3) were fabricated with the biocompatible resin and immersed in sterile PBS. 300 μL of PBS extract was removed at predetermined time points (3, 24, and 48h) and split into two parts (100 μL and 200 μL)³⁸. Circular discs were also printed and placed in the bottom of the well to examine the cell growth. The cytotoxic effect of the PBS extracts and the printed samples was assessed using the TR146 cell line and the viability was determined with the MTT method. The cells were cultured in DMEM supplemented with 10% FBS and 1%

penicillin/streptomycin (100 U/ml) and seeded in 96-well plates at a density of 10^4 cells/well. After 24h in culture to allow attachment, the cells were treated with the samples in question and incubated at 37 °C for additional 24h. At the end of this treatment, the medium was removed and the cells were rinsed with PBS. MTT solution (5mg/mL) was added to the wells for further incubation at 37 °C. After 4h, the MTT solution was removed and DMSO was added to dissolve the formazan crystals. Following mild agitation for 15 min, the absorption was measured at 570 nm, using an ELISA plate reader.

Statistical analysis



The results are presented as mean \pm SD and all the experiments were conducted in triplicate. Unpaired Student's t-test was applied and statistical significance was indicated by $p < 0.05$.



Results and Discussion

Visual inspection of the printed MN devices with a microscope

Figure 1 depicts the printed MN devices. Reservoirs were designed and printed as a single device. Both reservoirs had attached luers to facilitate the connection between the needles and the liquid

containers. Both arrays were printed directly onto the platform. Array I had hexagonal needles (Figure 1) and the reservoir was designed with channels. Needle height, layer height, and tip diameter were measured to be approximately 692 μm , 48 μm , and 119 μm , respectively. Array II was designed with syringe-like needles. Dimensions such as their height, layer height, and tip diameter were approximately 853 μm , 45 μm and 197 μm , respectively. All the dimensions were in good agreement with the CAD model, demonstrating the good printability of the MNs. It is worth noting that while the aforementioned values provide a fair assessment of the printed needles' geometrical parameters, light microscopy systems used here were not optimised for measuring 3D objects (objects extending on Z-dimension). Inaccuracies associated with parallax effect and angle of projection could affect the accuracy of these figures. More accurate characterisation was conducted using volumetric imaging by means of μCT .





235

236 **Figure 1.** Morphology of the printed hexagonal hollow MNs. (A) The array of the MNs (7x7), (B)

237 the dimensions of the needle; height, and layer height, (C) the dimensions of the reservoir channels,

238 and (D) the MN device with array I.









Figure 2. Morphology of the printed syringe like hollow MNs. (A) The array of the MNs (7x7), (B) dimension of a single needle; height, layer height, and the hole diameter, (C) dimensions of the MN array, and (D) the MN device with array II.

Volumetric characterisation by means of μ CT

As per in the ‘microneedle design and fabrication’ section, all needles were designed to be 700 μ m long. Our analysis of all 49 needles on both designs showed consistently shorter needle lengths

which can be attributed to material shrinkage after curing. This shrinkage is owed to the shorter intermolecular distance of the molecules after polymerization³⁹. Measured length from needle's base to the tip was 0.565 ± 0.032 mm and 0.570 ± 0.033 for the hexagonal (array I) and syringe-like (array II) needle arrays respectively. Length variation amongst needles of the same type was 6% for both needle geometries with values ranging [25th – 75th percentile] between 55 – 59 mm and 55 – 60 mm for array I and array II respectively.

The two geometries differed significantly in terms of needle volume, with array I (hexagonal) being 0.107 ± 0.009 mm³ and array II (syringe-like) being 0.184 ± 0.019 mm³, a difference of 71.9 %. This can be attributed to the open-lumen design of the hexagonal needles (Figure 3), which lacks excess material around the 2/3 of the lumen. This is also reflected by the measured surface area per needle, with the hexagonal geometry showing a surface area of 1.456 ± 0.081 mm² compared to 2.729 ± 0.186 mm² of the syringe-like ones (87.4 % difference).




Figure 3. 3D volume rendering of (A) the hexagonal (array I) and (B) syringe-like (array II) needle geometries. Close-ups of each geometry are showing in inserts. Individual needles rendered using different colours for clarity.

In terms of the fluid supply reservoir structure, the channel design used on the hexagonal needle arrays (array I) was more susceptible to printing imperfections and incomplete clearing contaminants (Figure 4).






Figure 4. 3D volume rendering of the fluid supply reservoir rendered in turquoise of both array designs (**A** and **B**) and single CT slice across the centre of the reservoir (**C** and **D**). Note the printing imperfections such as channel narrowing and incomplete clearing contaminants within the channels on the channel design of the hexagonal needle array. Scale bar at 10 mm.

Mechanical properties

1
2
3
4 279 The mechanical strength of hexagonal and syringe-like MNs was measured using a tensile test
5
6
7 280 machine. Figure 5 depicts the results from the compression test conducted for array I and array I.
8
9
10 281 Both arrays experienced forces greater than MN arrays face during insertion to the buccal mucosa
11
12
13 282 ⁸. As shown in Figure 5, hexagonal MNs can withstand forces up to 240 N and syringe-like MNs
14
15
16
17 283 can bear up to 310 N. After that, both MNs are seriously damaged. Hexagonal MNs seem to
18
19
20 284 tolerate less force than syringe-like MNs, in spite of the fact that they are made of the same resin.
21
22
23 285 This is probably owed to the different shapes and needle tips of the two MNs. Studies have shown
24
25
26
27 286 that the tip sharpness significantly influences the mechanical behavior of the MN structures⁴⁰. The
28
29
30 287 smaller tip diameter of the hexagonal MNs is presumably the reason for the lower mechanical
31
32
33
34 288 strength. The MNs were evaluated after compression test using Scanning Electron Microscopy
35
36
37 289 (SEM). Figure 5B depicts the hexagonal MNs after compression. Fragments are visible around the
38
39
40 290 needle and the hole is almost closed due to compression of the needle. Figure 5C presents the
41
42
43
44 291 syringe-like MNs after testing.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



292



Figure 5. (A) Compression test of hexagonal and syringe-like MNs demonstrating force-displacement experimental data. SEM images after compression test of **(B)** hexagonal and **(C)** syringe-like MNs.

Penetration test and FEA simulations

The capability of the hollow MNs to perforate porcine buccal mucosa has been investigated through instrumented penetration tests, assisted by FEA simulations. The applied forces have been measured and compared between two different geometrical configurations of the MNs. In the first place, compression and nanoindentation mechanical testing techniques^{41–43} were conducted to measure the mechanical properties of the 3D printed resin material. The compressive strength and the modulus were determined to be 122 ± 6 MPa and the elastic modulus 3099 MPa. FEA models have been introduced to improve the calculation accuracy of the forces applied during porcine buccal mucosa penetration tests and an explicit dynamics analysis was performed on ANSYS code. The thickness of the buccal mucosa layer was considered to be 700 μm since the average thickness has been reported to be 729 ± 95 μm ⁴⁴. Material failure and an evolving contact surface between MNs and target was introduced to define the insertion of the MN array and the surface of the buccal

1
2
3
4 309 mucosa samples, which is governed by large deformations²⁴. A material erosion algorithm was
5
6
7 310 utilized to study the failure and separation of the material. The material erosion method removes
8
9
10 311 distorted elements during the solution, i.e. along the MN trajectory, based upon material failure
11
12
13 312 and separation due to fracturing of the surface of the buccal mucosa. Since the connective tissue
14
15
16
17 313 is not involved with failure and significant deformation, the first two layers, epithelium and basal
18
19
20 314 lamina, were modeled as hyperelastic materials^{26,38}. Hyperelastic material models can be generally
21
22
23
24 315 classified into two categories, mechanistic (micro-mechanical) and phenomenological (macro-
25
26
27 316 mechanical)⁴⁵. A hyperelastic material describes the stress–strain relationship using a continuous
28
29
30 317 function rather than one or a series of elastic constants, generating a true nonlinear map of
31
32
33
34 318 behavior⁴⁶. Therefore, in this study, a first order Ogden material model was applied to replicate
35
36
37 319 the exact mechanical behavior of buccal mucosa, in order to minimize the difference between the
38
39
40 320 simulated and the experimental load-deformation curves.
41
42
43
44 321 The experimental setup of the buccal penetration process is shown in Figures 6A. The force-
45
46
47 322 displacement responses for the MN configurations are demonstrated in Figure 6C. The results of
48
49
50 323 simulations are shown in Figure 6C and accurately curve-fitted the experimental force-deformation
51
52
53
54 324 data up to maximum force of 10 N. During the deformation phase, the force exponentially
55
56
57
58
59
60

increases as each MN is pressed against the buccal mucosa. The drops in the experimental force-deformation curve may be explained by local perforation of a single MN prior piercing the buccal mucosa from all MNs. Since the assumptions on the material parameters in the FEA model returned results that fitted the experimental data, the hyperelastic material model parameters of the buccal mucosa were considered optimal. These material model parameters returned a stress-strain peak values of 1.05MPa and 78.75% strain. These results are in agreement with values from literature⁴⁷. Microscopy images of the MNs were taken after the penetration test to examine their morphology (Figure 6D and 6E). Images show that there was a decrease in the needle length up to 30% for both hexagonal and syringe-like needles. The simulation of the penetration test revealed that the stress concentration was located at the tip of the MNs, as displayed by the equivalent stress results in Figure 7A and B This demonstrates the stress contouring of the FEA simulating the behavior of the MN at the last step of the penetration test simulation. The maximum stress experienced by the insertion process was calculated to be 33.6 MPa and 24.2 MPa for the hexagon shaped and syringe-like configuration, respectively. There is no concern regarding the concentration of the stress obtained at the tip area of the MN for both the configurations, since the ultimate compressive strength was measured 122 ± 6 MPa, as mentioned previously.






Figure 6. (A) Illustration of the penetration test using buccal mucosa, (B) the buccal mucosa after penetration showing the perforation sites, (C) force-deformation curve of both arrays fitted by FEA, (D) and (E) microscopy images of array I and array II respectively, after penetration test.




Figure 7. Stress distribution of (A) hexagon and (B) syringe-like hollow MN at the last step of the simulation of buccal mucosa penetration using FEA.

353 Permeation studies

354 Permeation studies were conducted using Franz diffusion cells. Porcine buccal mucosa was
355 mounted between the donor and the acceptor, with the epithelium side facing the donor. The MN
356 devices were connected to the syringe pumps and diffused the solutes across the buccal epithelium.
357 Two different molecules namely FITC-dextran and calcein were tested to evaluate their
358 permeability using the printed MN devices. Different flow rates were tested for pumping, namely
359 0.5, 0.2, 0.05 mL/min using FITC-Dextran 4.4 kDa as model compound. High flow rates resulted
360 in leakage and in poor permeability for FITC-dextran as shown in Figure 8B. Previously, it has
361 been reported that high volumes of injected liquids leak out from tissues causing a non-uniform
362 distribution of the drug³³. However, a flow rate of 0.05 mL/min led to higher permeability values
363 and was further selected as the optimal flow rate for further evaluation of the MN devices. Both
364 hexagonal and syringe-like needles pierced the buccal tissue for 30 and 60 sec and the results are
365 depicted in Figure 8C and 8D. As evidenced from Figure 8C, FITC-dextran exhibited a two-fold
366 increased permeability after piercing for 30 and 60 sec with both arrays, compared to the control
367 group (t-test, $p < 0.05$). Despite the large molecular weight of FITC-dextran (4000 Da), it can easily
368 permeate across the membranes and its permeability is increased after MN insertion⁴⁸. However,


1
2
3
4 369 piercing for 60 sec does not show a significant increase in FITC's permeation neither for the MNs
5
6
7 370 nor for the control group (t-test $p>0.05$). This can be attributed to the retraction of the MN devices
8
9
10 371 immediately after piercing. It has been reported that the flow rate progressively increases with
11
12
13 372 needle retraction⁴⁹ and as shown in Figure 8B, higher flow rates result in leakages. Thus, it is
14
15
16
17 373 presumed that after 60 sec of piercing leakages occur that affect the permeation profile of FITC.
18
19
20 374 Furthermore, findings suggest that fluid flow into tissue samples at a constant pressure, decreases
21
22
23
24 375 over time⁴⁹, indicating that piercing time over 30 sec cannot increase the permeability of the model
25
26
27 376 dye. The current results imply that the volume of the lumen [(array I (hexagonal) 0.107 mm³ and
28
29
30 377 array II (syringe-like) 0.184 mm³], the structural features of the microneedles and the force
31
32
33
34 378 displacement responses of these microneedles have little effect to the permeation of this dye across
35
36
37 379 porcine epithelium and the increased transport is the due to flow rate in both cases. It appears that
38
39
40 380 the permeation of FITC-Dextran 4kDa across the porcine epithelium is governed by the diffusion
41
42
43
44 381 of the solute through the paracellular pathway which ultimately affect the transport rate of the
45
46
47 382 active prevailing the other parameters. Previous studies have shown that comparable permeability
48
49
50 383 values were obtained for FITC- Dextran 4 kDa and FITC-dextran 10 kDa as measured by flux
51
52
53
54 384 studies across buccal epithelium suggesting paracellular transport of these solutes. The authors
55
56
57
58
59
60

hypothesized that if the transport of the dyes would follow the transcellular pathway the differences in the permeability values would be more pronounced⁵⁰.

The picture was different for calcein transport studies across porcine epithelium. Calcein is a small hydrophilic molecule with poor permeability across cellular membranes and it is often used as a marker to examine *in vitro* the barrier integrity^{51,52}. As shown in Figure 8D, no appreciable amounts of calcein were delivered by passive diffusion. Significantly higher transport rates compared to the control were obtained after piercing for 30 and 60 sec upon application of the syringe-like microneedles (array II) (t-test $p < 0.05$) where the transport rate was increased 10 fold and 1000 fold respectively implying that piercing for longer time augment the solute to enter the perforation sites and finally permeate the tissue resulting to significantly higher permeation rates (t-test $p < 0.05$) over time.

In a similar manner increased transport rates were observed upon application of hexagonal-like microneedles (array I) as a function of piercing time. Longer piercing time seem to facilitate the transport of calcein through the tissue, in contrast with the results for FITC-dextran. This is probably attributed to the lower molecular weight of calcein and the fact that it is transported across the epithelium through the holes created from the MNs. Array I also seem to have increased

1
2
3
4 401 permeability for calcein in 30 sec compared to array II ($p < 0.05$), while after 60 sec the
5
6
7 402 permeability for both arrays is approximately the same ($p > 0.05$). As shown previously in
8
9
10 403 penetration test, the sharpness and the length of the needles is decreased after piercing the buccal
11
12
13 404 tissue (Figure 6D and 6E). This deformation leads to similar transport values for calcein in 60 sec.
14
15
16
17 405 In 30 sec, the needles seem to keep their integrity and differences in permeability values occur.
18
19
20 406 Overall, these results show that both MN devices can significantly increase the permeability of
21
22
23 407 both molecules after a short piercing time. In addition to that, the results demonstrate that these
24
25
26
27 408 devices might be utilized for buccal delivery of actives with both high and low molecular weight
28
29
30 409 thus increasing their permeability across buccal epithelium.
31
32
33
34 410
35
36
37 411
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



8/Figure 8. (A) Permeation study of the MN devices using Franz diffusion cells and syringe pump. The pump setting was 0.05 mL/min. (B) The cumulative amount of FITC permeated ($\mu\text{g}/\text{cm}^2$) with the three different flow rates. High flow rates resulted in leakages and poor permeation of FITC. (C) Cumulative amount of FITC and (D) calcein after piercing for 30 and 60 sec.

Histological evaluation

To confirm the safety of the MNs after piercing the porcine buccal mucosa, histological evaluation was conducted for both MN arrays, using hematoxylin-eosin staining. Figure 9 depicts the microscopy images after piercing the buccal tissue for 30 and 60 sec. Piercing for 30 sec revealed

no damage to the mucosa while piercing for 60 sec showed a local epithelium detachment (Figure 9B), while a pattern of the MNs is visible in Figure 9D. These results show that the MN devices do not injure severely the buccal epithelium, which can recover from the MN piercing.




Figure 9. Histological evaluation after piercing with (A) array I for 30 sec, (B) array I for 60 sec, (C) array II for 30 sec, and (D) array II for 60 sec.

Cell viability

Viability studies of TR146 cells, following the application of liquid resin, printed films, and PBS extracts, are presented in Figure 10. No obvious cytotoxicity was observed upon incubation for

24h with the tested samples. Incubation of the cells with the printed films shows a small increase in cell growth, compared with the positive control, indicating the safety of the printed devices as buccal drug delivery systems. The presence of monomers did not have any cytotoxic effect, probably due to the short period of exposure (24h). These results confirmed the cytocompatibility of the commercial resin in TR146 cell cultures, which is a human cell line. In addition to that, MN devices are designed only for a few seconds administration to the buccal tissue suggesting that the printed devices are safe for buccal administration.




Figure 10. Assessment of cell viability (%) of TR146 cultures exposed to incubation for 24h with printed films, PBS cube extracts and liquid resin, as indicated above.

440

441 **Conclusions**

442 3D printed hollow MN devices were successfully fabricated using DLP printing. Two different

443 shapes of needles were designed a conventional shape (syringe-like) and a hexagonal shape that it

444 was firstly introduced in the present study. Both arrays had attached reservoirs designed with

445 lumen for the hexagonal needles and a simple tank for the syringe-like needles. Microscopy studies

446 showed the good printability of the material and the shape fidelity of the printed objects with their

447 CAD model. The MNs were evaluated regarding their mechanical properties to ensure that they

448 are able to pierce the buccal tissue without breaking and leaving fragments in the oral cavity that

449 may result in toxicity. μ CT studies provided a detail imaging of the MNs and their reservoirs with

450 accurate dimensional characterization of the printed needles. Penetration test and FEA simulations

451 confirmed the ability of the MNs to penetrate the buccal mucosa and permeability studies indicated

452 that the printed devices could significantly increase the permeability of actives with high and low

453 molecular weights. Moreover, the shape of the needles, the piercing time and the flow rate play a

454 crucial role in the model dyes' permeability and needs to be further evaluated. In hollow MNs, the

455 size and place of the pore is very important and requires a detail assessment regarding the piercing

1
2
3
4 456 time into the tissue. Finally, histological and cell studies confirmed that the produced devices are
5
6
7 457 safe and hold promise for the buccal administration of actives to special populations.
8
9

10 458
11
12

13
14 459 **AUTHOR INFORMATION**
15
16

17 460 **Corresponding Author:** Prof. Dimitrios G. Fatouros, e-mail: dfatouro@pharm.auth.gr
18
19
20

21 461 **Present Addresses:** Department of Pharmacy Division of Pharmaceutical Technology, Aristotle
22
23
24 462 University of Thessaloniki, Thessaloniki 54124, Greece
25
26
27

28 463
29
30

31 464 **Author Contributions**
32
33
34

35 465 The manuscript was written through contributions of all authors. All authors have given approval
36
37
38 466 to the final version of the manuscript.
39
40
41

42 467
43
44
45

46 468 **ACKNOWLEDGMENTS**
47
48

49 469 The authors acknowledge the μ -VIS X-ray Imaging Centre at the University of Southampton,
50
51
52 470 founding partner of UK National Research Facility for lab-based X-ray Computed Tomography,
53
54
55
56
57
58
59
60

471 for the provision of the μ CT imaging facilities, data processing, and management infrastructure

472 and expertise.

473

474

475

476

477

478

479

480

481

482

483

484

485

486

REFERENCES

(1) Wang, S.; Jiang, L.; Meng, S.; Liu, C.; Wang, H.; Gao, Z.; Guo, J. Hollow Mesoporous Silica Nanoparticles-Loaded Ion-Crosslinked Bilayer Films with Excellent Mechanical Properties and High Bioavailability for Buccal Delivery. *Int. J. Pharm.* **2022**, *624*, 122056.

(2) Sahatsapan, N.; Pamornpathomkul, B.; Rojanarata, T.; Ngawhirunpat, T.; Poonkhum, R.; Opanasopit, P.; Patrojanasophon, P. Feasibility of Mucoadhesive Chitosan Maleimide-Coated Liposomes for Improved Buccal Delivery of a Protein Drug. *J. Drug Deliv. Sci. Techn.* **2022**, *69*, 103173.

(3) Tran, P. H. L.; Duan, W.; Tran, T. T. D. Recent Developments of Nanoparticle-Delivered Dosage Forms for Buccal Delivery. *Int. J. Pharm.* **2019**, *571*, 118697.

(4) Eleftheriadis, G. K.; Monou, P. K.; Bouropoulos, N.; Boetker, J.; Rantanen, J.; Jacobsen, J.; Vizirianakis, I. S.; Fatouros, D. G. Fabrication of Mucoadhesive Buccal Films for Local Administration of Ketoprofen and Lidocaine Hydrochloride by Combining Fused Deposition Modeling and Inkjet Printing. *J. Pharm. Sci.* **2020**, *109*(9), 2757-2766.

(5) Zewail, M. B.; F.Asaad, G.; Swellam, S. M.; Abd-allah, S. M.; K.Hosny, S.; Sallah, S. K.; E.Eissa, J.; S.Mohamed, S.; El-Dakroury, W. A. Design, Characterization and in Vivo

- 503 Performance of Solid Lipid Nanoparticles (SLNs)-Loaded Mucoadhesive Buccal Tablets for
- 504 Efficient Delivery of Lornoxicam in Experimental Inflammation. *Int. J. Pharm.* **2022**, *624*,
- 505 122006.
- 506 (6) Kraisit, P.; Hirun, N.; Mahadlek, J.; Limmatvapirat, S. Fluconazole-Loaded Solid Lipid
- 507 Nanoparticles (SLNs) as a Potential Carrier for Buccal Drug Delivery of Oral Candidiasis
- 508 Treatment Using the Box-Behnken Design. *J. Drug Deliv. Sci. Tech.* **2021**, *63*, 102437.
- 509 (7) Xu, J.; Strandman, S.; Zhu, J. X. X.; Barralet, J.; Cerruti, M. Genipin-Crosslinked Catechol-
- 510 Chitosan Mucoadhesive Hydrogels for Buccal Drug Delivery. *Biomaterials* **2015**, *37*, 395-
- 511 404.
- 512 (8) Oh, Y.-J.; Cha, H.-R.; Hwang, S. J.; Kim, D.-S.; Choi, Y.-J.; Kim, Y.-S.; Shin, Y.-R.;
- 513 Nguyen, T. T.; Choi, S.-O.; Lee, J. M.; Park, J.-H. Ovalbumin and Cholera Toxin Delivery
- 514 to Buccal Mucus for Immunization Using Microneedles and Comparison of Immunological
- 515 Response to Transmucosal Delivery. *Drug Del. Trans. Res.* **2021**, *11* (4), 1390-1400.
- 516 (9) Caffarel-Salvador, E.; Kim, S.; Soares, V.; Tian, R. Y.; Stern, S. R.; Minahan, D.; Yona, R.;
- 517 Lu, X.; Zakaria, F. R.; Collins, J.; Wainer, J.; Wong, J.; McManus, R.; Tamang, S.;
- 518 McDonnell, S.; Ishida, K.; Hayward, A.; Liu, X.; Hubálek, F.; Fels, J.; Vegge, A.;

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Frederiksen, M. R.; Rahbek, U.; Yoshitake, T.; Fujimoto, J.; Roxhed, N.; Langer, R.; Traverso, G. A Microneedle Platform for Buccal Macromolecule Delivery. *Sci. Adv.* **2021**, 7(4), eabe2620.

(10) Lee, Y.; Li, W.; Tang, J.; Schwendeman, S. P.; Prausnitz, M. R. Immediate Detachment of Microneedles by Interfacial Fracture for Sustained Delivery of a Contraceptive Hormone in the Skin. *J. Control. Rel.* **2021**, 337, 676-685.

(11) Choi, H.-J.; Yoo, D.-G.; Bondy, B. J.; Quan, F.-S.; Compans, R. W.; Kang, S.-M.; Prausnitz, M. R. Stability of Influenza Vaccine Coated onto Microneedles. *Biomaterials* **2012**, 33(14), 3756-3769.

(12) Sabri, A. H. B.; Anjani, Q. K.; Utomo, E.; Ripolin, A.; Donnelly, R. F. Development and Characterization of a Dry Reservoir-Hydrogel-Forming Microneedles Composite for Minimally Invasive Delivery of Cefazolin. *Int. J. Pharm.* **2022**, 617, 121593.

(13) Li, M.; Vora, L. K.; Peng, K.; Donnelly, R. F. Trilayer Microneedle Array Assisted Transdermal and Intradermal Delivery of Dexamethasone. *Int. J. Pharm.* **2022**, 612, 121295.

- 533 (14) Waghule, T.; Singhvi, G.; Dubey, S. K.; Pandey, M. M.; Gupta, G.; Singh, M.; Dua, K.
534 Microneedles: A Smart Approach and Increasing Potential for Transdermal Drug Delivery
535 System. *Biomed Pharmacother.* **2019**, *109*, 1249-1258.
- 536 (15) Guillot, A. J.; Cordeiro, A. S.; Donnelly, R. F.; Montesinos, M. C.; Garrigues, T. M.; Melero,
537 A. Microneedle-Based Delivery: An Overview of Current Applications and Trends.
538 *Pharmaceutics* **2020**, *12* (6), E569.
- 539 (16) Economidou, S. N.; Douroumis, D. 3D Printing as a Transformative Tool for Microneedle
540 Systems: Recent Advances, Manufacturing Considerations and Market Potential. *Adv. Drug*
541 *Deliv. Rev.* **2021**, *173*, 60-69.
- 542 (17) Eleftheriadis, G. K.; Genina, N.; Boetker, J.; Rantanen, J. Modular Design Principle Based
543 on Compartmental Drug Delivery Systems. *Adv Drug Deliv. Rev.* **2021**, *178*, 113921.
- 544 (18) Shin, D.; Hyun, J. Silk Fibroin Microneedles Fabricated by Digital Light Processing 3D
545 Printing. *J. Ind. Eng. Chem.* **2021**, *95*, 126-133.
- 546 (19) Adamov, I.; Stanojević, G.; Medarević, D.; Ivković, B.; Kočović, D.; Mirković, D.; Ibrić, S.
547 Formulation and Characterization of Immediate-Release Oral Dosage Forms with Zolpidem

1
2
3
4 548 Tartrate Fabricated by Digital Light Processing (DLP) 3D Printing Technique. *Int. J. Pharm.*
5
6
7 549 **2022**, *624*, 122046.
8
9
10 550 (20) Zhang, J.; Hu, Q.; Wang, S.; Tao, J.; Gou, M. Digital Light Processing Based Three-
11
12
13 551 Dimensional Printing for Medical Applications. *Int. J. Bioprint.* **2019**, *6*(1), 242.
14
15
16
17 552 (21) Evens, T.; Malek, O.; Castagne, S.; Seveno, D.; Van Bael, A. A Novel Method for Producing
18
19
20 553 Solid Polymer Microneedles Using Laser Ablated Moulds in an Injection Moulding Process.
21
22
23 554 *Manufactur. Letters* **2020**, *24*, 29-32.
24
25
26
27 555 (22) S.b.v.j., C.; Mannayee, G. Structural Analysis and Simulation of Solid Microneedle Array
28
29
30 556 for Vaccine Delivery Applications. *Mater. Today Proc.* **2022**, *65*, 3774-3779.
31
32
33
34 557 (23) Economidou, S. N.; Uddin, Md. J.; Marques, M. J.; Douroumis, D.; Sow, W. T.; Li, H.; Reid,
35
36
37 558 A.; Windmill, J. F. C.; Podoleanu, A. A Novel 3D Printed Hollow Microneedle
38
39
40 559 Microelectromechanical System for Controlled, Personalized Transdermal Drug Delivery.
41
42
43 560 *Add. Manufactur.* **2021**, *38*, 101815.
44
45
46
47 561 (24) Xenikakis, I.; Tzimtzimis, M.; Tsongas, K.; Andreadis, D.; Demiri, E.; Tzetzis, D.; Fatouros,
48
49
50 562 D. G. Fabrication and Finite Element Analysis of Stereolithographic 3D Printed
51
52
53
54
55
56
57
58
59
60

- 563 Microneedles for Transdermal Delivery of Model Dyes across Human Skin in Vitro. *Eur. J.*
564 *Pharm. Sci.* **2019**, *137*, 104976.
- 565 (25) Economidou, S. N.; Pere, C. P. P.; Reid, A.; Uddin, Md. J.; Windmill, J. F. C.; Lamprou, D.
566 A.; Douroumis, D. 3D Printed Microneedle Patches Using Stereolithography (SLA) for
567 Intradermal Insulin Delivery. *Mater Sci Eng C Mater Biol Appl.* **2019**, *102*, 743-755.
- 568 (26) Xenikakis, I.; Tsongas, K.; Tzimtzimis, E. K.; Katsamenis, O. L.; Demiri, E.; Zacharis, C.
569 K.; Georgiou, D.; Kalogianni, E. P.; Tzetzis, D.; Fatouros, D. G. Transdermal Delivery of
570 Insulin across Human Skin in Vitro with 3D Printed Hollow Microneedles. *J. Drug Del. Sci.*
571 *Techn.* **2022**, *67*, 102891.
- 572 (27) Mathew, E.; Pitzanti, G.; Gomes dos Santos, A. L.; Lamprou, D. A. Optimization of Printing
573 Parameters for Digital Light Processing 3D Printing of Hollow Microneedle Arrays.
574 *Pharmaceutics* **2021**, *13*(11), 1837.
- 575 (28) Xing, J.-F.; Zheng, M.-L.; Duan, X.-M. Two-Photon Polymerization Microfabrication of
576 Hydrogels: An Advanced 3D Printing Technology for Tissue Engineering and Drug
577 Delivery. *Chem. Soc. Rev.* **2015**, *44*(15), 5031-5039.

1
2
3
4 578 (29) Moussi, K.; Bukhamsin, A.; Hidalgo, T.; Kosel, J. Biocompatible 3D Printed Microneedles
5
6
7 579 for Transdermal, Intradermal, and Percutaneous Applications. *Adv. Eng. Mater.* **2020**, *22*
8
9
10 580 (2), 1901358.
11
12
13 581 (30) Gittard, S. D.; Ovsianikov, A.; Chichkov, B. N.; Doraiswamy, A.; Narayan, R. J. Two-Photon
14
15
16
17 582 Polymerization of Microneedles for Transdermal Drug Delivery. *Expert Opin. Drug Deliv.*
18
19
20 583 **2010**, *7*(4), 513-533.
21
22
23 584 (31) Di Carla Santos, S.; Fávaro-Moreira, N. C.; Abdalla, H. B.; Augusto, G. G. X.; Costa, Y. M.;
24
25
26
27 585 Volpato, M. C.; Groppo, F. C.; Gill, H. S.; Franz-Montan, M. A Crossover Clinical Study to
28
29
30 586 Evaluate Pain Intensity from Microneedle Insertion in Different Parts of the Oral Cavity. *Int.*
31
32
33 587 *J. Pharm.* **2021**, *592*, 120050.
34
35
36
37 588 (32) Daly, S.; Claydon, N. C. A.; Newcombe, R. G.; Seong, J.; Addy, M.; West, N. X. Randomised
38
39
40 589 Controlled Trial of a Microneedle Patch with a Topical Anaesthetic for Relieving the Pain of
41
42
43 590 Dental Injections. *J. Dent.* **2021**, *107*, 103617.
44
45
46
47 591 (33) Ma, Y.; Boese, S. E.; Luo, Z.; Nitin, N.; Gill, H. S. Drug Coated Microneedles for Minimally-
48
49
50 592 Invasive Treatment of Oral Carcinomas: Development and in Vitro Evaluation. *Biomed*
51
52
53 593 *Microdevices.* **2015**, *17*(2), 44.
54
55
56
57
58
59
60

- 594 (34) Wang, T.; Zhen, Y.; Ma, X.; Wei, B.; Li, S.; Wang, N. Mannosylated and Lipid A-
595 Incorporating Cationic Liposomes Constituting Microneedle Arrays as an Effective Oral
596 Mucosal HBV Vaccine Applicable in the Controlled Temperature Chain. *Colloids Surf. B*
597 *Biointerfaces*. **2015**, *126*, 520-530.
- 598 (35) Karavasili, C.; Eleftheriadis, G. K.; Gioumouxouzis, C.; Andriotis, E. G.; Fatouros, D. G.
599 Mucosal Drug Delivery and 3D Printing Technologies: A Focus on Special Patient
600 Populations. *Adv Drug Deliv Rev* **2021**, *176*, 113858.
- 601 (36) Li, X.-J.; Li, Y.; Meng, Y.; Pu, X.-Q.; Qin, J.-W.; Xie, R.; Wang, W.; Liu, Z.; Jiang, L.; Ju,
602 X.-J.; Chu, L.-Y. Composite Dissolvable Microneedle Patch for Therapy of Oral Mucosal
603 Diseases. *Biomater. Adv.* **2022**, *139*, 213001.
- 604 (37) Schindelin, J.; Rueden, C. T.; Hiner, M. C.; Eliceiri, K. W. The ImageJ Ecosystem: An Open
605 Platform for Biomedical Image Analysis. *Mol. Reprod. Dev.* **2015**, *82*, 518-529
- 606 (38) Xenikakis, I.; Tsongas, K.; Tzimtzimis, E. K.; Zacharis, C. K.; Theodoroula, N.; Kalogianni,
607 E. P.; Demiri, E.; Vizirianakis, I. S.; Tzetzis, D.; Fatouros, D. G. Fabrication of Hollow
608 Microneedles Using Liquid Crystal Display (LCD) Vat Polymerization 3D Printing
609 Technology for Transdermal Macromolecular Delivery. *Int. J. Pharm.* **2021**, *597*, 120303.

- 610 (39) Zhang, Q.; Weng, S.; Hamel, C. M.; Montgomery, S. M.; Wu, J.; Kuang, X.; Zhou, K.; Qi,
611 H. J. Design for the Reduction of Volume Shrinkage-Induced Distortion in Digital Light
612 Processing 3D Printing. *Extr. Mech. Letters* **2021**, *48*, 101403.
- 613 (40) Faraji Rad, Z.; Prewett, P. D.; Davies, G. J. Parametric Optimization of Two-Photon Direct
614 Laser Writing Process for Manufacturing Polymeric Microneedles. *Additive Manufact.* **2022**,
615 *56*, 102953.
- 616 (41) Mansour, M.; Tsongas, K.; Tzetzis, D.; Antoniadis, A. Mechanical and Dynamic Behavior
617 of Fused Filament Fabrication 3D Printed Polyethylene Terephthalate Glycol Reinforced
618 with Carbon Fibers. *Polymer-Plastics Techn. Eng.* **2018**, *57*(16), 1715-1725.
- 619 (42) Tzetzis, D.; Tsongas, K.; Mansour, G. Determination of the Mechanical Properties of Epoxy
620 Silica Nanocomposites through FEA-Supported Evaluation of Ball Indentation Test Results.
621 *Mater. Res.* **2017**, *20*, 1571-1578.
- 622 (43) Mansour, M.; Tsongas, K.; Tzetzis, D. Measurement of the Mechanical and Dynamic
623 Properties of 3D Printed Polylactic Acid Reinforced with Graphene. *Polymer-Plastics Tech.*
624 *Mater.* **2019**, *58*(11), 1234-1244.

- 625 (44) Meng-Lund, E.; Marxen, E.; Pedersen, A. M. L.; Müllertz, A.; Hyrup, B.; Holm, R.;
626 Jacobsen, J. Ex Vivo Correlation of the Permeability of Metoprolol Across Human and
627 Porcine Buccal Mucosa. *J. Pharm. Sci.* **2014**, *103* (7), 2053-2061.
- 628 (45) Steinmann, P.; Hossain, M.; Possart, G. Hyperelastic Models for Rubber-like Materials:
629 Consistent Tangent Operators and Suitability for Treloar's Data. *Arch. Appl. Mech.* **2012**, *82*
630 (9), 1183-1217.
- 631 (46) Chen, J.; Ahmad, R.; Li, W.; Swain, M.; Li, Q. Biomechanics of Oral Mucosa. *J. R. Soc.*
632 *Interface.* **2015**, *12* (109), 20150325.
- 633 (47) Goktas, S.; Dmytryk, J. J.; McFetridge, P. S. Biomechanical Behavior of Oral Soft Tissues.
634 *J. Periodontol.* **2011**, *82* (8), 1178-1186.
- 635 (48) Salamat-Miller, N.; Chittchang, M.; Johnston, T. P. The Use of Mucoadhesive Polymers in
636 Buccal Drug Delivery. *Adv. Drug Deliv. Rev.* **2005**, *57* (11), 1666-1691.
- 637 (49) Martanto, W.; Moore, J. S.; Kashlan, O.; Kamath, R.; Wang, P. M.; O'Neal, J. M.; Prausnitz,
638 M. R. Microinfusion Using Hollow Microneedles. *Pharm. Res.* **2006**, *23* (1), 104-113.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(50) Hoogstraate, A.J; Cullander, C.; Nagelkerke, J.F.; Senel, S.; Verhoef, J.C.; Junginger, H.E.; Boddé, H.E. Diffusion rates and transport pathways of fluorescein isothiocyanate (FITC)-labeled model compounds through buccal epithelium. *Pharm. Res.*, **1994** *11*(1):83-89.

(51) Macedo, A. S.; Castro, P. M.; Roque, L.; Thomé, N. G.; Reis, C. P.; Pintado, M. E.; Fonte, P. Novel and Revisited Approaches in Nanoparticle Systems for Buccal Drug Delivery. *J. Control. Rel.* **2020**, *320*, 125-141. <https://doi.org/10.1016/j.jconrel.2020.01.006>.

(52) Bibi, H. A.; di Cagno, M.; Holm, R.; Bauer-Brandl, A. Permeapad™ for Investigation of Passive Drug Permeability: The Effect of Surfactants, Co-Solvents and Simulated Intestinal Fluids (FaSSIF and FeSSIF). *Int. J. Pharm* **2015**, *493* (1), 192-197. <https://doi.org/10.1016/j.ijpharm.2015.07.028>.

Table of Contents



652

653